Press Release Details

Cerus Corporation Announces the Death of Dale A. Smith

July, 26 2001
Cerus Corporation (Nasdaq: CERS) today announced that Dale A. Smith, a member of the company's board of directors, has passed away.

"The Cerus family is extremely saddened by the passing of Dale, who has served on our board since 1994" said Stephen Isaacs, president and chief executive officer of Cerus. "Dale's wisdom, experience and guidance have been a tremendous asset to us over the years, and his counsel and friendship will be greatly missed. We offer our deepest condolences to Dale's family during this difficult time." Mr. Smith, age 69, joined Cerus' board of directors in March 1994. From 1978 to July 1995, Mr. Smith was Group Vice President of Baxter Healthcare Corporation where he was responsible for the biotechnology group and various corporate research groups including blood therapies, applied sciences, blood substitutes, venture technology and Baxter International Inc.'s European research center. Until his death on Monday, July 23, 2001, he also served as a director of Vical Inc. Mr. Smith held a B.A. in Business Administration from the University of Washington, Seattle.

ABOUT CERUS

Cerus Corporation is building on its leading position in the biopharmaceutical industry by offering medical systems and therapeutics that provide safer and more effective options to patients. The company is developing products based on its proprietary Helinxâ„¢ technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. These INTERCEPT Blood Systems are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.

Helinx is a trademark of Cerus Corporation

Intercept Blood System, Intercept Platelet System, Intercept Plasma System and Intercept Red Blood Cell System are trademarks of Baxter International, Inc. (NYSE: BAX)

Statements in this news release regarding commercialization, regulatory process and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any clinical trials, action by regulatory authorities, the uncertainty of market acceptance of any products or competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1999 Annual Report on Form 10-K and Cerus' Prospectus dated November 1, 2000.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600